Moreover, such compounds could also be used in other cancer types expressing CCK-2R, such as stromal ovarian cancer, astrocytoma and small cell lung cancer, which indicates a promising clinical value for CCK-2R ligands. This evidence concerns the gene CCKBR and small cell lung carcinoma.